Eczema and race as combined determinants for differential response to step-up asthma therapy - 01/08/14
Doi : 10.1016/j.jaci.2014.03.039
Jonathan Malka, MD a, b, David T. Mauger, PhD c, Ronina Covar, MD a, Nathan Rabinovitch, MD, MPH a, Robert F. Lemanske, MD d, Joseph D. Spahn, MD a, Robert C. Strunk, MD e, Robert S. Zeiger, MD, PhD f, Wayne J. Morgan, MD g, Stanley J. Szefler, MD a 
a Department of Pediatrics, National Jewish Health and University of Colorado Denver School of Medicine, Denver, Colo
b Pediatric Associates, Lauderdale Lakes, Fla
c Department of Health Evaluation Sciences, Pennsylvania State University, Hershey, Pa
d University of Wisconsin School of Medicine and Public Health, Madison, Wis
e Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Wash
f Department of Allergy, Kaiser Permanente and the Department of Pediatrics, University of California-San Diego, San Diego, Calif
g Arizona Respiratory Center, University of Arizona, Tucson, Ariz
| This study was supported by grants from the National Heart, Lung, and Blood Institute (grant nos. HL064307, HL064288, HL064295, HL064287, HL064305, and HL064313), the National Institute of Allergy and Infectious Diseases (grant no. T32AI007635), and the Clinical Translational Science Award program of the National Center for Research Resources (NCRR) (grant no. UL1-RR025011 [Wisconsin] and grant no. UL1-RR024992 [St Louis]). This study was performed in part by the General Clinical Research Centers at Washington University School of Medicine (M01-RR00036), and the University of Wisconsin (M01-RR03186). This study was also supported by Colorado CTSA (grant no. UL1 RR025780 from NCRR/National Institutes of Health [NIH] and grant no. UL1 TR000154 from NIH/NCATS). |
|
| Disclosure of potential conflict of interest: J. Malka has received payment for lectures from Aerocrine and Thermo Fisher. D. T. Mauger has received research support from the National Heart, Lung, and Blood Institute (NHLBI) and has consultant arrangements with GlaxoSmithKline, Merck, and Boehringer-Ingelheim R. Covar has consultant arrangements and has received research support from GlaxoSmithKline. R. F. Lemanske has received research support from the University of Wisconsin, the NHLBI, and Pharmaxis; has received travel support from the American Academy of Allergy, Asthma & Immunology (AAAAI); is employed by the University of Wisconsin; has received consultant fees from Merck, Sepracor, SA Boney and Associates, GlaxoSmithKline, the American Institute of Research, Genentech, Double Helix Development, and Boehringer-Ingelheim; has received speakers honoraria from Michigan Public Health, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health, California Chapter 4, the Colorado Allergy Society, the Pennsylvania Allergy Society, Howard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, APAPARI, and the Western Society of Allergy, Asthma, and Immunology; has received payment for manuscript preparation from the AAAAI; and has received royalties from Elsevier and UpToDate. J. D. Spahn has received consulting fees or honoraria from GlaxoSmithKline and is employed by National Jewish Health. R. C. Strunk has received research support from the NHLBI. R. S. Zeiger has received research support from the NHLBI, Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, and Thermo Fisher; is a board member for DBV Technologies; has consultant arrangements with GlaxoSmithKline, Genentech, Novartis, the NHLBI/Penn State, Aerocrine, AstraZeneca, and the Allergen Research Corporation; and has stock/stock options in DBV Technologies. W. J. Morgan has received research support from the National Institutes of Health; has received travel support from the National Institutes of Health/University of Arizona; has consultant arrangements with Genentech and the Cystic Fibrosis Foundation; is employed by the University of Arizona; has received research support from the National Institutes of Health, National Institutes of Health/Mount Sinai, Cystic Fibrosis Foundation/University of Washington, and the Cystic Fibrosis Foundation; has received payment for lectures from the American Thoracic Society, the AAAAI, the University of Tennessee, the University of Indiana, and the University of Alberta; and has received royalties from Elsevier. S. J. Szefler has consultant arrangements with Merck, Genentech, Boehringer-Ingelheim, and GlaxoSmithKline; has received research support from GlaxoSmithKline; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has submitted patents for beta adrenengic receptor polymorphism for the NHLBI Childhood Asthma Research and Education Network. N. Rabinovitch declares no relevant conflicts of interest. |
© 2014
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 134 - N° 2
P. 483-485 - août 2014 Retour au numéro
Article précédent
- Component-resolved diagnosis of wheat flour allergy in baker's asthma
- Cristina Gómez-Casado, María Garrido-Arandia, Catia Pereira, Manuela Catarino, Víctor Parro, Alicia Armentia, Santiago Quirce, Blanca Armentia, Paloma Barranco, Miguel Blanca, Paloma Campo, Araceli Díaz-Perales
- NOS3 polymorphism, lung function, and exposure in swine operations: Results of 2 studies
- Zhiwei Gao, James A. Dosman, Donna C. Rennie, David A. Schwartz, Ivana V. Yang, Jeremy Beach, Ambikaipakan Senthilselvan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?